Management of multiple myeloma

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The most recent NCCN Guidelines for Multiple Myeloma include a ranking of the many treatment options for various settings as "preferred," "other," and "useful in certain circumstances." For patients eligible for autologous stem cell transplant (ASCT), the preferred regimen remains bortezomib/lenalidomide/dexamethasone (category 1) or bortezomib/cyclophosphamide/dexamethasone. Upfront ASCT also remains a preferred strategy for patients who are transplant-eligible, despite highly effective newer agents such as induction therapy. Double (tandem) ASCT may benefit patients with high-risk cytogenetics, such as 17p deletion. Lenalidomide maintenance is the standard posttransplant approach and results in improved progression-free and overall survivals. For relapsed disease, a host of new agents have been shown to improve outcomes, mostly in combination with bortezomib or lenalidomide, but their selection depends largely on response and tolerability to prior therapies.

Original languageEnglish (US)
Pages (from-to)624-627
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number5S
StatePublished - May 1 2018

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Management of multiple myeloma'. Together they form a unique fingerprint.

Cite this